MagicMed Shortcuts Commercialization Timeline with University Agreement


Ryan Allway

November 4th, 2020

App, Exclusive, Psychedelics, Top Story


Most pharmaceutical and biotech investors are familiar with long commercialization timelines, but there are a few ways to shortcut the process. For example, the Food and Drug Administration provides Fast Track, Breakthrough Therapy, Accelerated Approval and Priority Review designations for certain therapies targeting life-threatening conditions.

MagicMed Industries Inc., a developer of licensable psychedelic molecular derivatives, shortcut its commercialization timeline via a Research Contract and Facilities Use Agreement with the University of Calgary to support the development of its Psybrary™.

Let’s take a closer look at this agreement and what it means for the company as it gears up to go public in the middle of next year.

Agreement Provides Research Support

MagicMed has been focused on the development of the Psybrary™, a library of psychedelic molecular derivatives that it hopes to license to partners to commercialize. Since these molecules are patentable—unlike natural compounds—with unique properties, they are ideally suited for pharmaceutical companies to develop into psychedelic-based mental health therapies.

The company’s recent agreement with the University of Calgary will provide it with further scientific and laboratory support to accelerate development of the Psybrary™ and shortcut its commercialization timeline. Through the agreement, the company will be able to leverage new state of the art equipment and draw upon world-class expertise at the university.

“The additional resources that the University of Calgary is providing to MagicMed complement and enhance our strengths,” says Dr. Joseph Tucker, CEO MagicMed. “This collaboration places MagicMed in a position to expand the breadth and depth of the psychedelic derivatives contained in the MagicMed Psybrary™.”

Click here to receive and investor presentation and corporate updates

Psybrary’s Unique Business Model

MagicMed’s team has been creating and patenting new molecular derivatives over the past 25 years with a focus on opiates, cannabinoids and ephedra. In particular, Chief Scientific Officer Dr. Peter Facchini is a recognized leader in the development of new molecular derivatives with over 160 scientific papers and 20 patents in the field.

MagicMed’s Place within the Process – Source: Investor Presentation

The Psybrary™ forms the basis of a unique business model capable of generating high-margin recurring revenue over time. By licensing derivative molecules, the company plans to generate licensing fees, milestone payments and blue-sky royalties when commercial products are launched into the market—all with minimal capital expenditures.

In addition to high margin revenue, the company works with a number of commercialization partners, which provides built-in diversification. Investors don’t have to bet all of their money on the success of one clinical trial, but rather, invest in a number of clinical trials run by partners where MagicMed retains the potential for royalty income.

Click here to receive and investor presentation and corporate updates

Looking Ahead

MagicMed Industries has shortcut its commercialization timeline with University of Calgary agreement. Over the next year, the company plans to expand its Psybrary™ with new patent filings, onboard its first partner, achieve a positive cash flow and publicly list during the first or second quarter—enabling retail investors to participate in the upside potential.

Investors may want to keep an eye on the company as it gears up for a public listing due to its multiple indications, partnership strategies, de-risked revenue model with blue sky potential and its conservative capital markets strategy geared toward generating near-term positive cash flow and long-term shareholder value.

For more information, visit the company’s website or download their investor presentation.

Disclaimer

The above article is sponsored content. CannabisFN.com and CFN Media, have been hired to create awareness. Please follow the link below to view our full disclosure outlining our compensation: https://cannabisfn.com/legal-disclaimer/

This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.

About Ryan Allway

Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.


Network Partners

Follow Us on Social Media

About CFN Media Group

CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.

Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.

Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer

loading